Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;46(8):3596-3614.
doi: 10.1007/s00261-021-03095-8. Epub 2021 Apr 28.

Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma

Affiliations
Review

Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma

Zersenay Alem et al. Abdom Radiol (NY). 2021 Aug.

Abstract

Transarterial radioembolization with yttrium-90 microspheres is an established therapy for hepatocellular carcinoma. Post-procedural imaging is important for the assessment of both treatment response and procedural complications. A variety of challenging treatment-specific imaging phenomena complicate imaging assessment, such as changes in tumoral size, tumoral and peritumoral enhancement, and extrahepatic complications. A review of the procedural steps, emerging variations, and timelines for post-treatment tumoral and extra-tumoral imaging changes are presented, which may aid the reporting radiologist in the interpretation of post-procedural imaging. Furthermore, a description of post-procedural complications and their significance is provided.

Keywords: Post-radioembolization CT findings; Radioembolization; SIRT; TARE; Yttrium; y90.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34. - PubMed - DOI
    1. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol. 2001 Sep;35(3):421–30.
    1. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011 Mar;53(3):1020–2. - PubMed - DOI
    1. Riaz A. Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma. JAMA. 2010 Mar 17;303(11):1062. - PubMed - PMC - DOI
    1. Saini A, Wallace A, Alzubaidi S, Knuttinen MG, Naidu S, Sheth R, et al. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma. J Clin Med. 2019 Jan 7;8(1):55. - PMC - DOI

MeSH terms

Substances

LinkOut - more resources